Cargando…

AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors

BACKGROUND: Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs. METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chang-Lu, Zhao, Yi-Zhuo, Zhang, Qin, Zeng, Wan-Qin, Jia, Tian-Ying, Zhu, Lei, Fang, Wen-Tao, Fu, Xiao-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792827/ http://dx.doi.org/10.21037/med-22-ab002

Ejemplares similares

AB002. Biomarkers for prostate cancer
por: Shindel, Alan
Publicado: (2016)

Salvage treatment of relapsed/refractory LCH
por: Seo, Jong Jin
Publicado: (2016)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

AB002. AUA guideline: update on Peyronie’s disease
por: Lue, Tom F.
Publicado: (2018)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
por: Kaimila, Bongani, et al.
Publicado: (2017)

AB002. Management of three types of priapism: 2015 update
por: Lue, Tom F.
Publicado: (2015)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant
por: Iqbal, Nida, et al.
Publicado: (2014)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
por: Thumallapally, Nishitha, et al.
Publicado: (2016)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

AB012. Automated histologic subtyping of thymic epithelial tumors with deep learning
por: Dolezal, James M., et al.
Publicado: (2022)

AB008. Activated pathways of Thymic Epithelial Tumors: a RYTHMIC study
por: Benitez, Jose Carlos, et al.
Publicado: (2022)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
por: Cui, Qingli, et al.
Publicado: (2021)

Salvage therapy of osimertinib plus anlotinib in advanced lung adenocarcinoma with leptomeningeal metastasis: A case report
por: Wu, Kai, et al.
Publicado: (2022)

AB002. Human penile allotransplantation: an emerging option for major genital loss
por: Burnett, Arthur L.
Publicado: (2017)

AB002. Quality of life is inversely related to income in patients with cutaneous lupus
por: Prasad, Smriti, et al.
Publicado: (2021)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies
por: Suzuki, Mikito, et al.
Publicado: (2019)

AB007. Expression of trophoblastic antigen 2 (Trop2) in thymic epithelial tumors
por: Yeung, Vincent, et al.
Publicado: (2022)

Transformation from Small Cell to Squamous Cell Carcinoma in a Thymic Carcinoma Patient with a Durable Response to Anlotinib: A Case Report
por: Qin, Wenru, et al.
Publicado: (2022)

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
por: Arcaini, Luca, et al.
Publicado: (2017)

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)
por: Shi, Yuankai, et al.
Publicado: (2021)

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
por: Wu, Di, et al.
Publicado: (2020)

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

AB004. Radiotherapy for thymic epithelial tumors: what is the optimal dose?—a systematic review
por: Angrisani, Antonio, et al.
Publicado: (2022)

AB003. Benefits of proton radiotherapy in thymic epithelial tumors using the model-based approach
por: Peeters, Stephanie T. H., et al.
Publicado: (2022)

Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
por: Jia, Wenqing, et al.
Publicado: (2022)

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
por: Stadtmauer, Edward A, et al.
Publicado: (2009)

Treating second‐relapsed/refractory first‐relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
por: Merli, Pietro
Publicado: (2022)

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis
por: Li, Shuo, et al.
Publicado: (2023)

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
por: Ng, M, et al.
Publicado: (2005)

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2021)

Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
por: Lessi, Federica, et al.
Publicado: (2021)

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
por: Ju, Hee Young, et al.
Publicado: (2022)

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
por: Mühleck, Regina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ot33d578c6bhmip490krthb1s